<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Crispr Therapeutics Ag — News on 6ix</title>
<link>https://6ix.com/company/crispr-therapeutics-ag</link>
<description>Latest news and press releases for Crispr Therapeutics Ag on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 16:35:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/crispr-therapeutics-ag" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835598778dffbe2df0eb153.webp</url>
<title>Crispr Therapeutics Ag</title>
<link>https://6ix.com/company/crispr-therapeutics-ag</link>
</image>
<item>
<title>Arrayed CRISPR Screening Market Presents Lucrative Opportunities Through 2026-2030: Total Revenue to Grow by $1.64 Billion at 17.7% CAGR</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/arrayed-crispr-screening-market-presents-lucrative-opportunities-through-2026-2030-total-revenue-to-grow-by-dollar164-billion-at-177percent-cagr</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/arrayed-crispr-screening-market-presents-lucrative-opportunities-through-2026-2030-total-revenue-to-grow-by-dollar164-billion-at-177percent-cagr</guid>
<pubDate>Mon, 20 Apr 2026 16:35:00 GMT</pubDate>
<description>Industry poised for growth, driven by advancements in precision drug discovery, rising gene therapy investments, and personalized medicine adoption Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Report 2026" has been added</description>
</item>
<item>
<title>CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team</description>
</item>
<item>
<title>CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550</description>
</item>
<item>
<title>CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-announces-proposed-convertible-senior-notes-offering</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-announces-proposed-convertible-senior-notes-offering</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer,</description>
</item>
<item>
<title>CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-business-reports-213000439</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-business-reports-213000439</guid>
<pubDate>Thu, 12 Feb 2026 21:30:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We made meaningful advances across multiple clinical and preclinical progr</description>
</item>
<item>
<title>CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-highlights-strategic-priorities-133600518</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-highlights-strategic-priorities-133600518</guid>
<pubDate>Mon, 12 Jan 2026 13:36:00 GMT</pubDate>
<description>-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeuti</description>
</item>
<item>
<title>CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating</description>
</item>
<item>
<title>CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-broad-update-zugocaptagene-geleucel-zugo-cel-formerly</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-broad-update-zugocaptagene-geleucel-zugo-cel-formerly</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical</description>
</item>
<item>
<title>CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously</description>
</item>
<item>
<title>CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-announces-positive-phase-1-clinical-data-ctx310r-demonstrating</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-announces-positive-phase-1-clinical-data-ctx310r-demonstrating</guid>
<pubDate>Sat, 08 Nov 2025 05:00:00 GMT</pubDate>
<description>-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310®</description>
</item>
<item>
<title>CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-presents-new-preclinical-data-ctx460tm-demonstrating-vivo-gene</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-presents-new-preclinical-data-ctx460tm-demonstrating-vivo-gene</guid>
<pubDate>Fri, 10 Oct 2025 04:00:00 GMT</pubDate>
<description>-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460,</description>
</item>
<item>
<title>CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-present-preclinical-data-alpha-1-antitrypsin-deficiency-aatd</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-present-preclinical-data-alpha-1-antitrypsin-deficiency-aatd</guid>
<pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating</description>
</item>
<item>
<title>CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-and-sirius-therapeutics-announce-first-patient-dosed-phase-2</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-and-sirius-therapeutics-announce-first-patient-dosed-phase-2</guid>
<pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company</description>
</item>
<item>
<title>CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-present-late-breaking-data-american-heart-association-aha</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-present-late-breaking-data-american-heart-association-aha</guid>
<pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating</description>
</item>
<item>
<title>CRISPR Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-participate-upcoming-investor-conferences-2025-09-02</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-participate-upcoming-investor-conferences-2025-09-02</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating</description>
</item>
<item>
<title>CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2025</guid>
<pubDate>Mon, 04 Aug 2025 04:00:00 GMT</pubDate>
<description>-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected</description>
</item>
<item>
<title>Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/oruka-therapeutics-announces-promotion-of-laura-sandler-to-chief-operating-officer</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/oruka-therapeutics-announces-promotion-of-laura-sandler-to-chief-operating-officer</guid>
<pubDate>Tue, 01 Jul 2025 20:01:00 GMT</pubDate>
<description>MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience across clinical operat</description>
</item>
<item>
<title>CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-named-times-most-influential-companies-list-2025-2025-06-30</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-named-times-most-influential-companies-list-2025-2025-06-30</guid>
<pubDate>Mon, 30 Jun 2025 04:00:00 GMT</pubDate>
<description>ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating</description>
</item>
<item>
<title>CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-reports-positive-additional-phase-1-data-ctx310tm-targeting</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-reports-positive-additional-phase-1-data-ctx310tm-targeting</guid>
<pubDate>Thu, 26 Jun 2025 04:00:00 GMT</pubDate>
<description>-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak</description>
</item>
<item>
<title>CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies</title>
<link>https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-and-sirius-therapeutics-announce-multi-target-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/crispr-therapeutics-ag/news/crispr-therapeutics-and-sirius-therapeutics-announce-multi-target-collaboration</guid>
<pubDate>Mon, 19 May 2025 04:00:00 GMT</pubDate>
<description>-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small</description>
</item>
</channel>
</rss>